Biotech Values

[DFRAI]

MNTA valuation

2.4 billion US sales
assume 50% sales
1.2 billion split worst case would be 10%, maybe 20% for hybrid and best would be 45%

*worst case would be 120 million per year to MNTA which would support 20-25 dollar per share price

**hybrid case would be 240 million or 45-60 per share

***best case of 45% or about 550 million would translate to 100-130 per share - which this would not last more than a year as Sanofi would introduce AG

If and when they get copaxone - 2 billion, 50% share and 50% split - mnta looks to add another 500 million in revenue per year _ hope Markman hearing goes their way and they get approved next summer by FDA

A lot of streching of course, but possible and voila in 2 years they could be making obscene amounts of cash - something like 700 million in profits - can we dream more than 20 per share???????????